This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Centre National De La Recherche Scientifique, The University of Nantes, Université Du Mans. Active years: 2025.
Company Filing History:
1 out of 5,383 
1 out of 156 
1 out of 15 Years Active: 2025
Title: Benoit Chenais: Innovator in Pharmaceutical Chemistry
Introduction
Benoit Chenais is a notable inventor based in Le Mans, France. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the treatment of proliferative diseases. His innovative work has led to the development of a unique patent that addresses critical health challenges.
Latest Patents
Benoit Chenais holds a patent for "Disulfonate stilbenes for use in the treatment of proliferative diseases." This patent includes compounds of a general formula where R and R' are independently selected from hydrogen and pharmaceutically acceptable cations. Additionally, R and R' are identical and selected from amide, carbamate, sulphonamide, azido, cyano, and halide. The patent also describes a pharmaceutical composition that may include another active ingredient, particularly an antineoplastic agent. This composition is intended for use as a medicament, especially in the treatment of proliferative diseases such as cancer.
Career Highlights
Throughout his career, Benoit Chenais has worked with esteemed institutions, including the University of Nantes and the Centre National de la Recherche Scientifique. His research and innovations have contributed to advancements in medical treatments and pharmaceutical applications.
Collaborations
Benoit has collaborated with notable colleagues such as Pierre Weigel and Fabrice Fleury. These partnerships have enhanced his research efforts and expanded the impact of his work in the scientific community.
Conclusion
Benoit Chenais is a distinguished inventor whose work in pharmaceutical chemistry has the potential to improve treatment options for proliferative diseases. His innovative patent and collaborations reflect his commitment to advancing medical science.